NCT06162377 2025-12-17
Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.
M.D. Anderson Cancer Center
Phase 4 Recruiting
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Tianjin Medical University Cancer Institute and Hospital
The First Affiliated Hospital of Dalian Medical University
Mercy Research
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh